The role of captodiamine in the withdrawal from long-term benzodiazepine treatment
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Discontinuation of benzodiazepines can be associated with the emergence of a withdrawal syndrome which compromises successful termination of treatment. The objective of the present study was to evaluate whether a six week administration of captodiamine during benzodiazepine discontinuation could prevent emergence of a benzodiazepine withdrawal syndrome and thus facilitate discontinuation of these drugs. SUBJECTS AND METHODS: A controlled, randomised, double-blind trial of captodiamine versus placebo was conducted in 81 subjects presenting mild to moderate anxiety and treated for at least 6 months with a stable dose of benzodiazepine. Each subject was gradually weaned from benzodiazepines over a 14 day period using a tapering dose schedule and received captodiamine (150 mg/d) or placebo for 45 days from the beginning of the weaning period. OUTCOME MEASURES: The primary outcome criterion was the extent of withdrawal symptoms assessed using the Tyrer Benzodiazepine Withdrawal Symptom Questionnaire. Secondary outcome criteria were; self-evaluation of tension, anxiety, drowsiness and slowing of physical and mental performance using visual analogue scales; quality of sleep using the Spiegel questionnaire; anxiety using the Hamilton Anxiety Rating Scale; and cognitive function using a driving stimulation test. RESULTS: Analysis of the primary study criterion revealed a statistically significant difference (p < 0.0001) in the emergence of withdrawal symptoms between the two groups in favour of captodiamine at two, six and eight weeks following initiation of therapy. These results were supported by significant beneficial effects of captodiamine on the majority of secondary outcome measures. The switch to captodiamine was associated with an improvement in vigilance, which may be an advantage for the overall safety of the anxiolytic treatment, for example with regard to road safety. Discontinuation of captodiamine was not associated with the emergence of rebound anxiety. CONCLUSION: Captodiamine represents an interesting strategy for achieving benzodiazepine substitution with a low risk of dependence or impairment of cognitive function. Further clinical studies addressing the anxiolytic activity and safety of captodiamine in such subjects are merited.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One potential candidate for treatment of withdrawal symptoms in these patients is gabapentin, which works similarly to the neurotransmitter GABA [68].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [68]
In the citing paper
“However, Flumazenil carries a high risk of seizures, so one must be cautious when administering this drug [68].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [68]
In the citing paper
“IV infusion of this medication has been shown to decrease aggression during BZD withdrawals by self-report in one study [68].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [68]
In the citing paper
“Additionally, these patients are more likely to have comorbid substance use disorders and anxiety disorders so it can be harder to find an efficacious treatment for their withdrawal symptoms [68].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [68]
In the citing paper
“However, this study was limited by a small sample size, so further randomized clinical trials need to be conducted to assess the efficacy of gabapentin treatment in BZD -dependent MMT patients [68].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [68]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Drugs and Falls in Older People: A Systematic Review and Meta‐analysis: I. Psychotropic Drugs
Leipzig, R. M., Cumming, R. G., & Tinetti, M. E. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb01898.x · Cited by 1,153
Benzodiazepines: use, abuse, and consequences.
Woods, J. H., Katz, J. L., & Winger, G. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00468-5 · Cited by 560
Benzodiazepines of Long and Short Elimination Half-life and the Risk of Hip Fracture
Ray, W. A. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03430230088031 · Cited by 548
Keltner, N. L. (1993) · Cited by 530
Psychoactive Drugs and the Risk of Injurious Motor Vehicle Crashes in Elderly Drivers
Ray, W. A., Fought, R. L., & Decker, M. D. (1992) · American Journal of Epidemiology · doi:10.1093/aje/136.7.873 · Cited by 417
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-3-426_1 · Cited by 320
Gradual Withdrawal of Diazepam after Long-Term Therapy
Tyrer, P., Owen, R., & Dawling, S. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92355-3 · Cited by 271
The benzodiazepine withdrawal syndrome
PÉTURSSON, H. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03743.x · Cited by 246
Research works printed but not linked: 9
- Lister RG, 1988, Psychopharmacol Ser, 6, 117
- Garriot JC, 1977, J Forensic Sci, 22, 283
- Dietch J, 1983, Hosp Community Psychiatry, 34, 1139
- Rickels K, 1984, Psychopharmacol Bull, 20, 608
- Zarifian E, 1998, Bull Acad Natl Med, 182, 1439
- De Gier JJ, 1988, European Council (Pompidou Group) P-PG/Circrout (98), 1, 1
- Ansseau M, 1993, J Clin Psychiatry, 54, 189
- Weidmann H, 1953, J Pharmacol Exp Therap, 108, 201
- Pentney BH, 1960, Practitioner, 185, 218
Cited by
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
“However, Flumazenil carries a high risk of seizures, so one must be cautious when administering this drug [68].”
BackgroundMethodInfluentialWithdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318
“[43-50] Many ed as a ‘pure’ antagonist, subsequent work in both other studies were excluded for a variety of reasons, animals and humans has suggested that flumazenil is including inappropriate outcome measures, setting a mixed agonist/antagonist, depending partly on and selection of participants.[51-73] Several of th…”
ResultEffectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis
Parr, J. M., Kavanagh, D. J., Cahill, L., Mitchell, G., & Young, R. M. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02364.x · Cited by 212
“25) Captodiamine [39] Not estimable”
BackgroundPharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users
Baandrup, L., Ebdrup, B. H., Rasmussen, J. Ø., Lindschou, J., Gluud, C., & Glenthøj, B. Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011481.pub2 · Cited by 128
Metadata
- Authors
- Mercier-Guyon, C., Chabannes, J. P., & Saviuc, P.
- Affiliations
- Centre Hospitalier Universitaire de Grenoble (FR)
- Corresponding author
- Mercier-Guyon, C.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2004-07-14
- Volume
- 20
- Issue
- 9
- Pages
- 1347-1355
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2114226116
- Cited by
- 24
- References
- 43
- Citations by year
- 2025: 2 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 1 · 2018: 2 · 2016: 1 · 2015: 1 · 2014: 1 · 2013: 2
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- benzodiazepine withdrawal syndrome, benzodiazepine tapering, benzodiazepine discontinuation, anxiety, sustained attention, cognitive function, sleep quality, anxiolytics
- MeSH terms
- Adult, Anxiety, Benzodiazepines, Double-Blind Method, Ethylamines, Female, Humans, Male, Substance Withdrawal Syndrome, Sulfides, Anti-Anxiety Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of captodiamine in the withdrawal from long-term benzodiazepine treatment. https://app.cochat.ai/papers/10.1185/030079904125004457
- The paper
- Mercier-Guyon, C., Chabannes, J. P., & Saviuc, P. (2004). The role of captodiamine in the withdrawal from long-term benzodiazepine treatment. Current Medical Research and Opinion. https://doi.org/10.1185/030079904125004457
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.